UBS Group
YARW

UBS Group’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

UBS Group’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108K Buy
3,596
+2,341
+187% +$68.3K ﹤0.01% 6969
2025
Q4 		$36.4K Buy
1,255
+1,144
+1,031% +$23K ﹤0.01% 7399
2025
Q3 		$1.87K Buy
+111
New +$3.63K ﹤0.01% 9268
2025
Q2 		– Sell
-152
Closed -$12K – 10881
2025
Q1 		$12K Buy
152
+139
+1,069% +$17.1K ﹤0.01% 8521
2024
Q4 		$2.11K Buy
+13
New +$1.7K ﹤0.01% 9109
2024
Q3 		– Sell
-501
Closed -$47.5K – 9292
2024
Q2 		$49.4K Buy
+501
New +$62.5K ﹤0.01% 6700
2024
Q1 		– Sell
-17
Closed -$1.83K – 8930
2023
Q4 		$1.97K Buy
17
+13
+325% +$2.03K ﹤0.01% 8185
2023
Q3 		$744 Sell
4
-18
-82% -$3.93K ﹤0.01% 8303
2023
Q2 		$4.45K Buy
22
+15
+214% +$3.99K ﹤0.01% 7532
2023
Q1 		$1.12K Sell
7
-54
-89% -$9.7K ﹤0.01% 8804
2022
Q4 		$8.2K Buy
61
+49
+408% +$9.79K ﹤0.01% 8806
2022
Q3 		$2K Hold
12
– – ﹤0.01% 9783
2022
Q2 		$4K Buy
+12
New +$5.03K ﹤0.01% 9147
2022
Q1 		– Hold
0
– – – 10965
2021
Q4 		– Sell
-4
Closed -$4.29K – 10757
2021
Q3 		$6K Sell
4
-4
-50% -$7.76K ﹤0.01% 8454
2021
Q2 		$26K Buy
8
+1
+14% +$3.96K ﹤0.01% 7084
2021
Q1 		$46K Sell
7
-34
-83% -$247K ﹤0.01% 6648
2020
Q4 		$236K Buy
41
+15
+58% +$94.3K ﹤0.01% 5142
2020
Q3 		$155K Sell
26
-3
-10% -$17.5K ﹤0.01% 4943
2020
Q2 		$178K Buy
29
+18
+164% +$122K ﹤0.01% 4886
2020
Q1 		$109K Buy
11
+6
+120% +$94.1K ﹤0.01% 5222
2019
Q4 		$89K Buy
5
+1
+25% +$16.7K ﹤0.01% 6067
2019
Q3 		$59K Buy
4
+3
+300% +$48.4K ﹤0.01% 6106
2019
Q2 		$28K Hold
1
– – ﹤0.01% 6390
2019
Q1 		$15K Sell
1
-1
-50% -$24K ﹤0.01% 6553
2018
Q4 		$36K Buy
+2
New +$44.8K ﹤0.01% 6354
2018
Q3 		– Hold
0
– -$7K – 8298
2018
Q2 		– Hold
0
– – – 7352
2018
Q1 		– Hold
0
– – – 6671

Other funds holding YARW

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group's YARW Position: Q1 2026 in Review

UBS Group increased its Yarrow Bioscience, Inc. Common Stock (YARW) stake by 187% in Q1 2026, buying an estimated $68.3K and bringing the position to 3,596 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #6969.

UBS Group first reported a position in YARW in Q4 2018 and has held it in 25 quarters since. The position peaked at $236K in Q4 2020. 42 funds tracked by Wall St. Rank hold YARW as of Q1 2026.

  • UBS Group held 3,596 shares of Yarrow Bioscience, Inc. Common Stock worth $108K as of Q1 2026.
  • UBS Group bought 2,341 Yarrow Bioscience, Inc. Common Stock shares in Q1 2026, an estimated $68.3K.
  • Yarrow Bioscience, Inc. Common Stock made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6969 holding.
  • UBS Group first reported a position in Yarrow Bioscience, Inc. Common Stock in Q4 2018 and has held it in 25 quarters since.
  • UBS Group's Yarrow Bioscience, Inc. Common Stock position peaked at $236K in Q4 2020.
  • 42 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.